Skip to Main Content
DownloadHi-Res Photo

Hari Deshpande, MD

Associate Professor of Medicine (Medical Oncology)

Contact Information

Hari Deshpande, MD

Mailing Addresses

  • PO Box 208028

    333 Cedar Street,

    New Haven, CT 06520-8028

    United States

  • Smilow Cancer Hospital at Yale New Haven

    4th Floor Multidisciplinary Clinic

    New Haven, CT 06511

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

I have been involved in clinical trials since joining Yale in 2004. My main interests are in sarcoma, thyroid cancers and cancers of unknown primary. I am also part of the head and neck and GU cancer teams and participate in their trials. My current research includes new treatments for thyroid cancers as well as types of sarcoma. I will also be also looking at the effect of COVID on the inpatient medical oncology consult service at Yale. I am fortunate to be an investigator in over 20 trials of different therapies in Sarcomas, head and neck cancers, thyroid cancers and GU cancers

Extensive Research Description

The clinical trials I am involved with change frequently - I encourage interested people to view the Yale Cancer Center Clinical Trials website. http://yalecancercenter.org/patient/trials/

Sarcoma; Cancers of unknown primary; Thyroid cancer

Coauthors

Research Interests

Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Soft Tissue Neoplasms; Sarcoma, Synovial; Thyroid Neoplasms; Neoplasms, Connective and Soft Tissue; Liposarcoma, Myxoid

Selected Publications

  • Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma.Hasan NM, Sharma A, Ruzgar NM, Deshpande H, Olino K, Khan S, Ahuja N. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma. Oncotarget 2021, 12: 1566-1579. PMID: 34381562, PMCID: PMC8351604, DOI: 10.18632/oncotarget.28032.
  • Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, JCO2101829. PMID: 35394800, DOI: 10.1200/JCO.21.01829.
  • Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022 PMID: 35488876, DOI: 10.1002/hed.27077.

Clinical Trials

ConditionsStudy Title
Larynx; Lip, Oral Cavity and PharynxA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Larynx; Lip, Oral Cavity and PharynxA Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
ProstateA Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
Larynx; Lip, Oral Cavity and PharynxA Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)
Lip, Oral Cavity and Pharynx; Other Skin; Soft TissueA Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Corpus Uteri; Larynx; Lung; Soft Tissue; Unknown SitesA Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Thyroid; Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Esophagus; Larynx; Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
Other SkinA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Bones and Joints; Kidney; Soft Tissue; PediatricsPhase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
LungA Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
Lip, Oral Cavity and PharynxPhase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Larynx; Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Larynx; Lip, Oral Cavity and PharynxPhase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lip, Oral Cavity and PharynxIndividualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Edit Profile